I-Mab Biopharma US Limited
Clinical trials sponsored by I-Mab Biopharma US Limited, explained in plain language.
A biopharmaceutical company developing immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Hard-to-Treat cancers: experimental drug enters human trials Results expected Dec 2026 (estimated)
-
New drug combo aims to slow stomach cancer progression
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…
Phase 2 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…
Phase 1 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC